[go: up one dir, main page]

SI2358675T1 - 4-(2-(2-fluorofenoksimetil)fenil)piperidinske spojine - Google Patents

4-(2-(2-fluorofenoksimetil)fenil)piperidinske spojine

Info

Publication number
SI2358675T1
SI2358675T1 SI200930435T SI200930435T SI2358675T1 SI 2358675 T1 SI2358675 T1 SI 2358675T1 SI 200930435 T SI200930435 T SI 200930435T SI 200930435 T SI200930435 T SI 200930435T SI 2358675 T1 SI2358675 T1 SI 2358675T1
Authority
SI
Slovenia
Prior art keywords
phenylcpiperidine
fluorophenoxymethyl
compounds
phenylcpiperidine compounds
Prior art date
Application number
SI200930435T
Other languages
English (en)
Inventor
Lori Jean Patterson
Eric L. Stangeland
Sheila Zipfel
Daniel D. Long
Original Assignee
Theravance, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41666409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2358675(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance, Inc. filed Critical Theravance, Inc.
Publication of SI2358675T1 publication Critical patent/SI2358675T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
SI200930435T 2008-11-14 2009-11-13 4-(2-(2-fluorofenoksimetil)fenil)piperidinske spojine SI2358675T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11454108P 2008-11-14 2008-11-14
EP09752688.3A EP2358675B9 (en) 2008-11-14 2009-11-13 4-[2-(2-Fluorophenoxymethyl)phenyl]piperidine compounds
PCT/US2009/064308 WO2010056941A1 (en) 2008-11-14 2009-11-13 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds

Publications (1)

Publication Number Publication Date
SI2358675T1 true SI2358675T1 (sl) 2013-01-31

Family

ID=41666409

Family Applications (3)

Application Number Title Priority Date Filing Date
SI200930435T SI2358675T1 (sl) 2008-11-14 2009-11-13 4-(2-(2-fluorofenoksimetil)fenil)piperidinske spojine
SI200930419T SI2358676T1 (sl) 2008-11-14 2009-11-13 Kristalinična oblika 4-(2-(2-fluorofenoksimetil)fenil)piperidinske spojine
SI200930543T SI2358674T1 (sl) 2008-11-14 2009-11-13 Postopek za pripravo 4-(2-(2-fluorofenoksimetil)fenil)piperidinskih spojin

Family Applications After (2)

Application Number Title Priority Date Filing Date
SI200930419T SI2358676T1 (sl) 2008-11-14 2009-11-13 Kristalinična oblika 4-(2-(2-fluorofenoksimetil)fenil)piperidinske spojine
SI200930543T SI2358674T1 (sl) 2008-11-14 2009-11-13 Postopek za pripravo 4-(2-(2-fluorofenoksimetil)fenil)piperidinskih spojin

Country Status (28)

Country Link
US (23) US8247433B2 (sl)
EP (3) EP2358674B1 (sl)
JP (6) JP5598798B2 (sl)
KR (3) KR101656339B1 (sl)
CN (3) CN102209712B (sl)
AR (3) AR074128A1 (sl)
AU (3) AU2009313951B2 (sl)
BR (3) BRPI0921595B8 (sl)
CA (3) CA2742114C (sl)
CL (2) CL2011001088A1 (sl)
CO (2) CO6361988A2 (sl)
CY (3) CY1113622T1 (sl)
DK (3) DK2358675T3 (sl)
ES (3) ES2396583T3 (sl)
HR (3) HRP20120920T1 (sl)
IL (2) IL212230A (sl)
MX (3) MX2011005089A (sl)
MY (2) MY151211A (sl)
NZ (2) NZ592413A (sl)
PL (3) PL2358676T3 (sl)
PT (3) PT2358675E (sl)
RU (2) RU2503662C2 (sl)
SG (1) SG171311A1 (sl)
SI (3) SI2358675T1 (sl)
SM (3) SMT201200063B (sl)
TW (3) TWI443087B (sl)
WO (3) WO2010056939A1 (sl)
ZA (1) ZA201103495B (sl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5598798B2 (ja) 2008-11-14 2014-10-01 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ４−［２−（２−フルオロフェノキシメチル）フェニル］ピペリジン化合物を調製するためのプロセス
US8778949B2 (en) * 2010-01-11 2014-07-15 Theravance Biopharma R&D Ip, Llc 1-(2-phenoxymethylphenyl)piperazine compounds
ES2543064T3 (es) * 2010-03-22 2015-08-14 Theravance Biopharma R&D Ip, Llc Compuestos de 1-(2-fenoximetilheteroaril)piperidina y piperazina
MX2012012245A (es) * 2010-04-22 2012-12-17 Theravance Inc Combinacion de una reabsorcion de inhibidor de serotonina y norepirefrina y un agonista opioide para el tratamiento del dolor.
CA2830882C (en) 2011-03-22 2021-03-16 Dinesh Barawkar Substituted fused tricyclic compounds, compositions and medicinal applications thereof
US9544692B2 (en) * 2012-11-19 2017-01-10 Bitwave Pte Ltd. System and apparatus for boomless-microphone construction for wireless helmet communicator with siren signal detection and classification capability
FI3506900T3 (fi) * 2016-08-30 2024-11-29 Theravance Biopharma R&D Ip Llc Ampreloksetiini käytettäväksi neurogeenisen ortostaattisen hypotension
US10640467B2 (en) 2018-06-01 2020-05-05 Theravance Biopharma R&D Ip, Llc Process for preparing 2-(1-(tert-butoxycarbonyl)piperidine-4-yl)benzoic acid
CA3252091A1 (en) 2022-03-28 2023-10-05 Theravance Biopharma R&D Ip, Llc Ampreloxetine is intended for use in the treatment of multiple system atrophy.
CN114957098B (zh) * 2022-06-02 2024-03-29 和鼎（南京）医药技术有限公司 一种制备喷他佐辛中间体的方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
DE2549999A1 (de) 1975-11-07 1977-05-12 Boehringer Mannheim Gmbh Piperidin-derivate und verfahren zu ihrer herstellung
US4241071A (en) 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4198417A (en) 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
EP0190496A3 (en) 1984-12-13 1987-05-27 Beecham Group Plc Piperidine derivatives having a gastro-intestinal activity
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
DE3835291A1 (de) * 1988-04-19 1989-11-02 Bayer Ag 1,3-disubstituierte pyrrolidine
GB9324018D0 (en) * 1993-11-23 1994-01-12 Merck Sharp & Dohme Therapeutic agents
EP1097137A1 (en) * 1998-07-10 2001-05-09 AstraZeneca AB N-substituted naphthalene carboxamides as neurokinin-receptor antagonists
GB9922521D0 (en) 1998-10-07 1999-11-24 Zeneca Ltd Compounds
ES2157148B1 (es) * 1998-11-18 2002-03-01 Faes Fabrica Espanola De Produ Nuevas piperidinas 4-sustituidas.
US6518284B2 (en) * 1998-11-18 2003-02-11 Faes, Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. 4-substituted piperidines
ID30204A (id) * 1999-12-27 2001-11-15 Japan Tobacco Inc Senyawa-senyawa cincin terfusi dan penggunaannya sebagai obat
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
US6630504B2 (en) 2000-08-31 2003-10-07 Pfizer Inc. Phenoxyphenylheterocyclyl derivatives as SSRIs
US7294637B2 (en) 2000-09-11 2007-11-13 Sepracor, Inc. Method of treating addiction or dependence using a ligand for a monamine receptor or transporter
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
ATE413882T1 (de) 2002-08-23 2008-11-15 Lilly Co Eli 2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin- wiederaufnahme-inhibitoren
PL1635828T3 (pl) * 2003-04-04 2008-10-31 H Lundbeck As Pochodne 4-(2-fenyloksyfenylo)-piperydyny lub 1,2,3,6-tetrahydropirydyny jako inhibitory wychwytu zwrotnego serotoniny
KR20050119682A (ko) * 2003-04-04 2005-12-21 하. 룬트벡 아크티에 셀스카브 세로토닌 재흡수 억제제로서 4-(2-페닐옥시페닐)-피페리딘또는 -1,2,3,6-테트라히드로피리딘 유도체
AU2004247487B2 (en) * 2003-06-17 2010-05-20 Pfizer Inc. N-pyrrolidin-3-YL-amide derivatives as serotonin and noradrenaline re-uptake inhibitors
TW200900399A (en) 2003-10-01 2009-01-01 Speedel Experimenta Ag Organic compounds
WO2005068447A1 (en) 2004-01-13 2005-07-28 Pfizer Limited Piperazine derivatives which exhibit activity as serotonin and noradrenaline re-upatke inhibitors
WO2005092835A1 (en) 2004-03-05 2005-10-06 Eli Lilly And Company Pharmaceutical compounds
GEP20084550B (en) 2004-04-30 2008-11-25 Warner Lambert Co Substituted morpholine compounds for the treatment of central nervous system disorders
GB0505437D0 (en) 2005-03-17 2005-04-20 Merck Sharp & Dohme Therapeutic agents
US20070142389A1 (en) * 2005-12-20 2007-06-21 Pfizer Inc. Piperidine derivatives
US20070249607A1 (en) * 2006-04-17 2007-10-25 Bristol-Myers Squibb Company Nk-1 and serotonin transporter inhibitors
CN101506164A (zh) 2006-08-23 2009-08-12 辉瑞产品公司 哌啶衍生物
CA2664245A1 (en) * 2006-09-27 2008-04-03 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor modulators
US8026257B2 (en) 2007-07-11 2011-09-27 Bristol-Myers Squibb Company Substituted heterocyclic ethers and their use in CNS disorders
WO2009081259A1 (en) 2007-12-21 2009-07-02 Pfizer Inc. Phenoxy-pyridyl derivatives
KR20110026481A (ko) 2008-06-20 2011-03-15 메타볼렉스, 인코포레이티드 아릴 ｇｐｒ１１９ 작동약 및 이의 용도
US7888386B2 (en) 2008-07-24 2011-02-15 Theravance, Inc. 3-(phenoxyphenylmethyl)pyrrolidine compounds
JP5598798B2 (ja) 2008-11-14 2014-10-01 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ４−［２−（２−フルオロフェノキシメチル）フェニル］ピペリジン化合物を調製するためのプロセス
US8778949B2 (en) 2010-01-11 2014-07-15 Theravance Biopharma R&D Ip, Llc 1-(2-phenoxymethylphenyl)piperazine compounds
ES2543064T3 (es) 2010-03-22 2015-08-14 Theravance Biopharma R&D Ip, Llc Compuestos de 1-(2-fenoximetilheteroaril)piperidina y piperazina
FI3506900T3 (fi) * 2016-08-30 2024-11-29 Theravance Biopharma R&D Ip Llc Ampreloksetiini käytettäväksi neurogeenisen ortostaattisen hypotension

Also Published As

Publication number Publication date
CA2742114A1 (en) 2010-05-20
NZ592543A (en) 2013-02-22
CN102216272B (zh) 2014-02-05
DK2358675T3 (da) 2013-01-14
TW201024263A (en) 2010-07-01
US20130030020A1 (en) 2013-01-31
BRPI0921593A2 (pt) 2015-08-18
US10946007B2 (en) 2021-03-16
PL2358676T3 (pl) 2013-03-29
AU2009313948B2 (en) 2015-03-12
JP2012508759A (ja) 2012-04-12
CY1113622T1 (el) 2016-06-22
HK1160448A1 (en) 2012-08-17
US12239638B2 (en) 2025-03-04
KR101656339B1 (ko) 2016-09-09
CN102209712B (zh) 2016-04-06
US10576073B2 (en) 2020-03-03
US10034870B2 (en) 2018-07-31
PT2358676E (pt) 2012-12-06
EP2358674A1 (en) 2011-08-24
JP2012508760A (ja) 2012-04-12
JP2014139209A (ja) 2014-07-31
CY1113855T1 (el) 2016-07-27
CN102216272A (zh) 2011-10-12
NZ592413A (en) 2013-02-22
MX2011005090A (es) 2011-09-06
US8802857B2 (en) 2014-08-12
AR114965A2 (es) 2020-11-11
HRP20120920T1 (hr) 2013-01-31
TWI461407B (zh) 2014-11-21
MX2011005088A (es) 2011-06-01
US20190134019A1 (en) 2019-05-09
TWI443087B (zh) 2014-07-01
CN102216271A (zh) 2011-10-12
CY1113623T1 (el) 2016-06-22
JP5598798B2 (ja) 2014-10-01
ES2396583T3 (es) 2013-02-22
EP2358675B1 (en) 2012-10-03
US20120277438A1 (en) 2012-11-01
RU2011123890A (ru) 2012-12-20
TWI441810B (zh) 2014-06-21
DK2358674T3 (da) 2013-04-08
CA2742105C (en) 2016-09-13
BRPI0921595B1 (pt) 2020-10-13
KR101656338B1 (ko) 2016-09-09
IL212452A0 (en) 2011-06-30
BRPI0921596B1 (pt) 2021-10-26
RU2515612C2 (ru) 2014-05-20
US10206913B2 (en) 2019-02-19
CA2739992C (en) 2016-09-20
MX2011005089A (es) 2011-07-29
KR20110082085A (ko) 2011-07-15
SI2358674T1 (sl) 2013-04-30
US10946006B2 (en) 2021-03-16
US10441579B2 (en) 2019-10-15
HRP20120897T1 (hr) 2012-12-31
HRP20130300T1 (hr) 2013-04-30
AU2009313951B2 (en) 2015-03-12
US20230201181A1 (en) 2023-06-29
KR20110082197A (ko) 2011-07-18
CA2742105A1 (en) 2010-05-20
CN102209712A (zh) 2011-10-05
BRPI0921596A2 (pt) 2018-03-20
MY151229A (en) 2014-04-30
CN102216271B (zh) 2013-09-25
US8604058B2 (en) 2013-12-10
AU2009313949B2 (en) 2015-03-19
BRPI0921593B8 (pt) 2021-05-25
US20140045892A1 (en) 2014-02-13
SI2358676T1 (sl) 2013-01-31
PT2358674E (pt) 2013-03-05
US10722504B2 (en) 2020-07-28
US8592596B2 (en) 2013-11-26
CO6361988A2 (es) 2012-01-20
AR074128A1 (es) 2010-12-22
BRPI0921595B8 (pt) 2021-05-25
US20180055830A1 (en) 2018-03-01
SMT201200063B (it) 2013-01-14
IL212230A0 (en) 2011-06-30
AU2009313949A1 (en) 2010-05-20
EP2358676B1 (en) 2012-10-10
US20140323735A1 (en) 2014-10-30
CL2011001088A1 (es) 2011-10-14
AR074350A1 (es) 2011-01-12
US20100125092A1 (en) 2010-05-20
US20210290608A1 (en) 2021-09-23
EP2358675B9 (en) 2019-09-11
US20140057944A1 (en) 2014-02-27
WO2010056941A1 (en) 2010-05-20
TW201022206A (en) 2010-06-16
US9073859B2 (en) 2015-07-07
DK2358676T3 (da) 2013-01-14
EP2358675A1 (en) 2011-08-24
CA2739992A1 (en) 2010-05-20
AU2009313951A1 (en) 2010-05-20
US20200316048A1 (en) 2020-10-08
SMT201200065B (it) 2013-03-08
US20100125093A1 (en) 2010-05-20
US20180289687A1 (en) 2018-10-11
EP2358674B1 (en) 2013-01-02
IL212230A (en) 2014-12-31
US8247433B2 (en) 2012-08-21
US9187423B2 (en) 2015-11-17
US20100125141A1 (en) 2010-05-20
SMT201300033B (it) 2013-05-06
TW201024264A (en) 2010-07-01
AU2009313948A1 (en) 2010-05-20
US20180050024A1 (en) 2018-02-22
US9675599B2 (en) 2017-06-13
BRPI0921593B1 (pt) 2021-05-04
HK1160449A1 (en) 2012-08-17
JP5529150B2 (ja) 2014-06-25
MY151211A (en) 2014-04-30
SG171311A1 (en) 2011-07-28
US8304432B2 (en) 2012-11-06
WO2010056939A1 (en) 2010-05-20
US9162982B2 (en) 2015-10-20
US20160022660A1 (en) 2016-01-28
US20240316024A1 (en) 2024-09-26
US11596624B2 (en) 2023-03-07
CA2742114C (en) 2016-09-13
US20160184288A1 (en) 2016-06-30
ES2401224T3 (es) 2013-04-17
JP2014101384A (ja) 2014-06-05
ZA201103495B (en) 2012-01-25
US20200316047A1 (en) 2020-10-08
KR101685186B1 (ko) 2016-12-09
RU2503662C2 (ru) 2014-01-10
JP5506813B2 (ja) 2014-05-28
ES2397247T3 (es) 2013-03-05
US10226454B2 (en) 2019-03-12
KR20110082196A (ko) 2011-07-18
RU2011123875A (ru) 2012-12-20
EP2358676A1 (en) 2011-08-24
PL2358674T3 (pl) 2013-06-28
JP2014098033A (ja) 2014-05-29
CL2011001093A1 (es) 2011-09-02
CO6361993A2 (es) 2012-01-20
US8304433B2 (en) 2012-11-06
HK1160452A1 (en) 2012-08-17
US20190142816A1 (en) 2019-05-16
PT2358675E (pt) 2012-12-12
US20130030185A1 (en) 2013-01-31
US20200000792A1 (en) 2020-01-02
JP2012508761A (ja) 2012-04-12
US11723900B2 (en) 2023-08-15
PL2358675T3 (pl) 2013-03-29
US20220087995A1 (en) 2022-03-24
WO2010056938A1 (en) 2010-05-20

Similar Documents

Publication Publication Date Title
GB0800035D0 (en) Compounds
GB0815947D0 (en) Compounds
GB0804702D0 (en) Compounds
GB0818072D0 (en) Compounds
SI2358675T1 (sl) 4-(2-(2-fluorofenoksimetil)fenil)piperidinske spojine
GB0814991D0 (en) Compounds
IL212171A0 (en) 1-phenylpyrrole compounds
GB0807103D0 (en) Compounds
GB0800367D0 (en) Compounds
GB0801220D0 (en) Compounds
GB0817982D0 (en) Compounds
GB0814990D0 (en) Compounds
GB0801265D0 (en) Compounds
GB0803496D0 (en) Compounds
GB0818064D0 (en) Compounds
GB0802587D0 (en) Compounds
GB0802586D0 (en) Compounds
GB0802192D0 (en) Compounds
GB0802191D0 (en) Compounds
GB0801596D0 (en) Compounds
GB0803495D0 (en) Compounds
GB0804064D0 (en) Compounds
GB0800961D0 (en) Compounds
GB0800841D0 (en) Compounds
GB0800455D0 (en) Compounds